Murky waters: post-approval regulatory activities and the § 271(e)(1) safe harbor *

USA - April 10 2013
On January 14, 2013, the U.S. Supreme Court refused to consider the U.S. Court of Appeals for the Federal Circuit's exclusion in Classen…

Co-authors: Ewa M. Davison.

US Supreme Court to weigh in on reverse payment deals *

USA - April 2 2013
On March 25, 2013, the U.S. Supreme Court heard oral argument in FTC v. Actavis, Inc., which is on appeal from the U.S. Court of Appeals for the…

Co-authors: Melanie L. Mayer.

Supreme Court allows generic manufacturers to challenge overbroad use codes *

USA - June 5 2012
The United States Supreme Court ruled unanimously on April 17, 2012 that a generic drug manufacturer may file a counterclaim to force correction of an overbroad use code that encompasses unclaimed methods of using the drug at issue.

Co-authors: Ewa M. Davison.

Supreme Court allows generic manufacturers to challenge overbroad use codes *

USA - April 18 2012
The United States Supreme Court has again reversed the Federal Circuit, ruling unanimously that a generic drug manufacturer may file a counterclaim to force correction of an overbroad use code that encompasses unclaimed methods of using the drug at issue. 

Co-authors: Heather N. Mewes, Ewa M. Davison.